|Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.||Exec. Chairman & Acting CEO||286k||N/A||1956|
|Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD||Fin. Director, Company Sec. & Non-Exec. Director||138k||N/A||1978|
|Mr. Robert Charles Bishop LLB (Hons)||Exec. Director||140.8k||N/A||N/A|
|Ms. Fiona Milner||Gen. Mang. of Epichem Pty Ltd||N/A||N/A||N/A|
|Dr. Gary Pitt||Head of Chemistry||N/A||N/A||N/A|
|Dr. James Rixson||Head of Production||N/A||N/A||N/A|
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.
PharmAust Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.